Glucotrack, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Glucotrack, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $589.5K | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $611.7K | Mar 30, 2018 |
| FY2017 | Dec 31, 2015 | $143.2K | Mar 30, 2018 |
| FY2016 | Dec 31, 2014 | $59.8K | Mar 31, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $208.0K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $43.5K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $589.5K | Apr 15, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.39M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($22.60M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($7.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.44M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($4.07M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.70M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.52M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($6.72M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $10.33M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($5.41M) | Mar 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.09M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($14.55M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($7.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.43M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($4.04M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($3.13M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.51M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($6.54M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $10.58M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($5.66M) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.81M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $9.50M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $4.70M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.97M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.81M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.53M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.61M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $3.03M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $3.21M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $2.88M | Mar 30, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $139.0K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $415.0K | Mar 31, 2022 |
| FY2017 | Dec 31, 2017 | $1.53M | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $1.13M | Mar 30, 2018 |
| FY2017 | Dec 31, 2015 | $1.13M | Mar 30, 2018 |
| FY2016 | Dec 31, 2014 | $230.8K | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | $1.04M | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $852.9K | Mar 31, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.24M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($12.49M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($6.56M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.73M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($3.77M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($3.50M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.90M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($4.89M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($5.90M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($5.31M) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $96.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $104.0K | Mar 30, 2026 |
| FY2023 | Dec 31, 2022 | $1.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $53.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $23.0K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $5.4K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $19.5K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $76.5K | Mar 30, 2018 |
| FY2017 | Dec 31, 2015 | $143.7K | Mar 30, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.84M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $5.93M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $4.91M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.44M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.27M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.61M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.10M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $688.2K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.67M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $2.46M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.01M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $18.93M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.71M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.21M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.11M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.62M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.51M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $3.56M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $4.82M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.37M | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.83M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($13.00M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $3.20M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $1.23M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $5.16M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $8.98M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($1.41M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($2.87M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2017 | ($16.57M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2016 | ($10.95M) | Apr 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($151.84M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($132.45M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($109.85M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($101.90M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($97.47M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($93.40M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($90.70M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($87.19M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($47.37M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($35.60M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.38M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $5.62M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $4.49M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.31M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.06M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $9.82M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $419.0K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $97.1K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $53.8K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $148.8K | Mar 30, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 4,106 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 34 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Apr 13, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | (4) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | (1) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | (1) | Mar 30, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 4,106 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 34 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | (4) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | (1) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | (1) | Mar 30, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 910,688 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 13,409 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 208,914 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 15.50M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 15.47M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 15.44M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 161.86M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | 141.63M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | 6.82M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 6.03M | Mar 30, 2018 |